Filings Soon As Biogen Snaps Up Ionis' Antisense Treatment

Promising top-line Phase III data have prompted Biogen to exercise an option to develop and commercialize Ionis's novel antisense treatment nusinersen for infantile-onset spinal muscular atrophy; filings are due shortly.

DNA
• Source: Shutterstock

Shares in Carlsbad, CA-based Ionis Pharmaceuticals Inc. (formerly ISIS Pharmaceuticals) shot up by more than 30% to close at $38.01 on Aug. 1 when it announced the initial data from its ENDEAR study of the antisense candidate nusinersen plus a $75m license fee payment from Biogen Inc.,which will now assume responsibility for the drug's development. Biogen's shares also received a 4% boost.

A pre-specified interim analysis has shown that babies with infantile-onset (consistent with Type 1) spinal muscular atrophy (SMA) receiving nusinersen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.